DDU of Nebulisers
The delivered dose testing of a nebulisers is carried out to determine the total amount of drug a patient might be expected to receive during a treatment period, rather than through one inhalation. Given the mode of operation of nebulisers, well-defined tidal breathing profiles for specific patient types are specified for testing. The two tests specified in the Pharmacopoeias to characterise delivered dose, Active Substance Delivery Rate and Total Active Substance Delivered, are based on tidal flow conditions generated by a breathing simulator, as opposed to fixed flow rates.
Breathing Simulator BRS 100i
View ProductFilter Holder and Adapter
View BrochureMouthpiece Adapter
View ProductAngle Adapter (for BRS 100i only)
View BrochureBRS 200i Breathing Simulator
View ProductLabel Printer
View BrochureAPSD of Nebulisers
View SystemBreathing Simulator BRS 100i
View ProductFilter Holder and Adapter
View BrochureMouthpiece Adapter
View ProductAngle Adapter (for BRS 100i only)
View BrochureBRS 200i Breathing Simulator
View ProductLabel Printer
View BrochureAPSD of Nebulisers
View SystemRelated Applications
We also offer a range of equipment for additional MDI testing application support:
Related Applications
Two factors have been identified as being critical to improving the clinical relevance of DDU testing and APSD measurement: realistic breathing profiles and realistic throat and nasal models.
View MoreRelated Applications
One of the main factors influencing the amount of inhaled drug available to the patient is the interface between the facemask and the patient. Investigating and defining the effect of a facemask to the product’s DDU and APSD is important for the product development.
View MoreRelated Services
Training
We offer a range of training courses, presentations and seminars covering a wide range of topics.
Find Out MoreServicing
A comprehensive range of both in-house and on-site product servicing options are available
Find Out MoreSupport
Our team of experienced technicians and engineers are on hand to help and advise
Find Out MoreRelated News & Resources
Copley introduces the new Patient Exhalation Simulator to help inhaler developers understand the impact of poor patient technique.
New product from Copley for quantifying the extent to which exhaling into a dry powder inhaler (DPI) compromises drug delivery.
Find Out MoreCopley introduces the new Flow Rate Sensor, a dedicated device for inhaler testing systems.
27 June 2023; Nottingham, UK: The new Flow Rate Sensor FRS is the latest addition to Copley Scientific’s orally inhaled and nasal drug product…
Find Out MoreThe new DUSA Shaker™ DTS 100i from Copley: For faster, safer, more repeatable inhaler testing
8th February 2023; Nottingham, UK: The DUSA Shaker™ DTS 100i is a new semi-automation solution from Copley Scientific, the global leader in inhaler and…
Find Out MoreCopley launches EnviroMate™, an efficient, benchtop environmental chamber for inhaler testing
14 September 2022; Nottingham, UK: EnviroMate™ is a benchtop environmental control chamber from Copley, the world’s leading manufacturer and supplier of inhaler testing equipment,…
Find Out MoreCopley Scientific joins the Industries Forum of the Taskforce for Lung Health
23 June 2021; Nottingham, UK: Copley Scientific has joined the Industries Forum of the Taskforce for Lung Health. The Taskforce is a collaboration of over…
Find Out MoreCopley announces a major upgrade of the world’s ‘go to’ inhaler testing portfolio
01 March 2021, Nottingham, UK: Copley Scientific, the global leaders in inhaler testing equipment, is marking the company’s 75th anniversary with a significant upgrade…
Find Out MoreNew e-Training service from Copley for pharmaceutical testing
14 January 2021; Nottingham, UK: Copley Scientific is now delivering e-Training, offering customers across the globe remote access to expert tuition on in vitro…
Find Out MoreAdvancing the science of OINDPs: Copley Scientific joins IPAC-RS
28 February 2018; Nottingham, UK: Copley Scientific, a global leader in the design and manufacture of inhaler testing equipment, is pleased to announce that…
Find Out MoreCopley Scientific introduces improved test set-up for more representative inhaled product testing
5 August 2014; Nottingham, UK: The desire to gain a better understanding of how inhaled products perform in patients has highlighted the importance and…
Find Out MoreMore precise nebuliser testing as Copley Scientific launches NGI Cooler
29 April 2009; Nottingham, UK: The new NGI Cooler from Copley Scientific is a practical, easy to use system that improves the accuracy and…
Find Out MoreWhite paper: October 2023
Understanding the links between drug delivery route and in vitro test methods In this white paper, we review the drug product characteristics that define…
Find Out MoreQ&A: OINDPnews 2022
Reducing Inhaler Testing Variability Through Test Environment Control In this Q&A with OINDPnews, our CEO Mark Copley answers questions about the importance of the…
Find Out MoreDDD 2021 Respiratory eBook Profile
Semi-Automating Inhaler Testing – A Good Idea, but Where to Start? Cascade impaction is a vital technique in the development and manufacture of orally…
Find Out MorePMPS Q&A (Samedan): April 2021
Putting Inhalers to the Test Anna Sipitanou has worked for Copley Scientific for four years, expanding her drug discovery and pharma science background. She…
Find Out MoreMicrobioz India: February 2021
A short Q&A with our CEO, Mark Copley, on inhaled product testing
Find Out MoreInhalation Article: December 2019
Optimizing the role of automation in variability reduction strategies for delivered dose uniformity (DDU) and aerodynamic particle size distribution (APSD) testing of inhaled drug…
Find Out MoreInhalation Article: April 2019
The regulatory landscape for OINDPs – the biggest shake-up in a generation?
Find Out MoreDrug Development & Delivery Article: April 2018
Optimizing the Application of In Vitro Test Methods for the Demonstration of Bioequivalence in Orally Inhaled Products
Find Out MorePMPS Article (Samedan): February 2018
Demonstrating Bioequivalence of Orally Inhaled Products Safe and cost-effective treatments for respiratory diseases are facing a growing demand. The demonstration of bioequivalence within locally…
Find Out MoreWhite Paper: February 2018
Optimising the application of in vitro test methods for the demonstration of BE in OIPs
Find Out MoreHave a question? Our friendly and experienced team are here to help.